Found this . Looks like MQG has lost it's enthusiasm for CIM . http://www.eurekareport.com.au/broker-alerts/macquarie-downgrades-cim-neutral-outperform
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%